...
首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II)
【24h】

A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II)

机译:一项随机和临床有效性试验,比较了两种药物遗传算法和标准护理对华法林剂量的个体化(CoumaGen-II)

获取原文
获取原文并翻译 | 示例
           

摘要

Background-Warfarin is characterized by marked variations in individual dose requirements and a narrow therapeutic window. Pharmacogenetics (PG) could improve dosing efficiency and safety, but clinical trials evidence is meager. Methods and Results-A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II) comprised 2 comparisons: (1) a blinded, randomized comparison of a modified 1-step (PG-1) with a 3-step algorithm (PG-2) (N=504), and (2) a clinical effectiveness comparison of PG guidance with use of either algorithm with standard dosing in a parallel control group (N=1866). A rapid method provided same-day CYP2C9 and VKORC1 genotyping. Primary outcomes were percentage of out-of-range international normalized ratios at 1 and 3 months and percentage of time in therapeutic range. Primary analysis was modified intention to treat. In the randomized comparison, PG-2 was noninferior but not superior to PG-1 for percentage of out-of-range international normalized ratios at 1 month and 3 months and for percentage of time in therapeutic range at 3 months. However, the combined PG cohort was superior to the parallel controls (percentage of out-of-range international normalized ratios 31% versus 42% at 1 month; 30% versus 42% at 3 months; percentage of time in therapeutic range 69% versus 58%, 71% versus 59%, respectively, all P<0.001). Differences persisted after adjustment for age, sex, and clinical indication. There were fewer percentage international normalized ratios 4 and ≤1.5 and serious adverse events at 3 months (4.5% versus 9.4% of patients, P<0.001) with PG guidance. Conclusions-These findings suggest that PG dosing should be considered for broader clinical application, a proposal that is being tested further in 3 major randomized trials. The simpler 1-step PG algorithm provided equivalent results and may be preferable for clinical application.
机译:背景-华法林的特征在于个体剂量需求的显着变化和狭窄的治疗窗口。药物遗传学(PG)可以提高给药效率和安全性,但临床试验证据很少。方法和结果-一项比较两种药物遗传学算法和标准护理个体化华法林剂量(CoumaGen-II)的随机临床疗效试验,包括2个比较:(1)改良的1步法(PG-1)与3步算法(PG-2)(N = 504),以及(2)在平行对照组(N = 1866)中使用标准剂量的两种算法进行PG指导的临床有效性比较。一种快速的方法提供了当日CYP2C9和VKORC1基因分型的功能。主要结果是在1个月和3个月时超出正常范围的国际标准化比例的百分比以及在治疗范围内的时间百分比。初步分析被修改为治疗意向。在随机比较中,PG-2在1个月和3个月时超出国际标准化比例的百分比以及在3个月时在治疗范围内的时间百分比方面均不低于PG-1,但并不优于PG-1。但是,合并后的PG队列优于平行对照组(超出范围的国际标准化比例在1个月时为31%对42%;在3个月时为30%对42%;在治疗范围内的时间百分比为69%对分别为58%,71%和59%,所有P <0.001)。调整年龄,性别和临床适应症后,差异仍然存在。在PG指导下,3个月时国际标准化比率4和≤1.5的百分比和严重不良事件较少(4.5%比9.4%的患者,P <0.001)。结论-这些发现表明,应考虑将PG剂量用于更广泛的临床应用,这一建议正在3个主要的随机试验中进行进一步测试。较简单的1步PG算法可提供相同的结果,并且可能更适合临床应用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号